

Exhibit E

PubMed
Central
Journal List
Search
Write to PMC

PNAS
Proceedings of the National Academy of Sciences
of the United States of America

PubMed
Central

Abstract
Full Text
Figures/Tables
PDF
Contents
Archive

PubMed

Articles by:

Farci, P.
Shimoda, A.
Wong, D.
Purcell, R.

and links to:

Related articles

Proc. Natl. Acad. Sci. USA. 1996 December 24; 93 (26): 15394-15399
Medical Sciences

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein

Patrizia Farci,^{*†} Atsushi Shimoda,^{*} Doris Wong,^{*} Teresa Cabezon,[‡]
Daniela De Gioannis,[§] Antonello Strazzera,[§] Yohko Shimizu,[¶] Max Shapiro,^{||}
Harvey J. Alter,^{**} and Robert H. Purcell^{*}

^{*}Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; [‡]SmithKline Beecham Biologicals, B-1330 Rixensart, Belgium; [§]Istituto di Medicina Interna, University of Cagliari, 09124 Cagliari, Italy; [¶]Department of Bacteriology, University of Tokyo, Tokyo 113, Japan; ^{||}Bioqual Inc., Rockville, MD 20852; and ^{**}Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892

[†] To whom reprint requests should be addressed at: Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 7, Room 200, 7 Center Drive, MSC 0740, Bethesda, MD 20892-0740.

Contributed by Robert H. Purcell, October 7, 1996

This article has been cited by other articles in PMC.

Abstract

The identification of the neutralization domains of hepatitis C virus (HCV) is essential for the development of an effective vaccine. Here, we show that the hypervariable region 1 (HVR1) of the envelope 2 (E2) protein is a critical neutralization domain of HCV. Neutralization of HCV *in vitro* was attempted with a rabbit hyperimmune serum raised against a homologous synthetic peptide derived from the HVR1 of the E2 protein, and the residual infectivity was evaluated by inoculation of HCV-seronegative chimpanzees. The source of HCV was plasma obtained from a patient (H) during the acute phase of posttransfusion non-A, non-B hepatitis, which had been titrated for infectivity in chimpanzees. The anti-HVR1 antiserum induced protection against homologous HCV infection in chimpanzees, but not against the emergence of

Top
Abstract
Introduction
MATERIALS AND
METHODS
RESULTS
DISCUSSION
References

neutralization escape mutants that were found to be already present in the complex viral quasispecies of the inoculum. The finding that HVR1 can elicit protective immunity opens new perspectives for the development of effective preventive strategies. However, the identification of the most variable region of HCV as a critical neutralization domain poses a major challenge for the development of a broadly reactive vaccine against HCV.

▶Top
▶Abstract
▶Introduction
MATERIALS AND
METHODS
▶RESULTS
▶DISCUSSION
▶References

Introduction

Hepatitis C virus (HCV) is an important cause of morbidity and mortality worldwide (1–3). Infection with HCV becomes chronic in >80% of the cases and is a major cause of liver cirrhosis (4) and hepatocellular carcinoma (5). Although the development of a broadly reactive vaccine would be the most effective method for its control, concerns have been raised because of the high degree of genetic heterogeneity of HCV (6) and the lack of protective immunity against reinfection (7, 8) or superinfection (9, 10) documented both in humans and in chimpanzees. Viral isolate-restricted neutralizing antibodies against HCV have been demonstrated recently in infected individuals (11, 12), but their molecular target is presently unknown.

Several observations have suggested that the hypervariable region 1 (HVR1) could be involved in the neutralization of HCV. This assumption is based on the fact that the HVR1, which is located at the N terminus of the envelope glycoprotein 2 (E2) gene and consists of 34 amino acids spanning map position 384–414 (13), is the most variable region of the HCV genome (14, 15), contains linear epitopes that are recognized by patients' antibodies (16–22) and mutates rapidly *in vivo* (23–26), suggesting that it is under the selective pressure of the host immune system. This hypothesis is further substantiated by the lack of variability in the HVR1 observed in an agammaglobulinemic patient over a period of 2.5 years (27). Recent data obtained *in vitro* suggest that antibodies, present in human sera and directed against the HVR1 as well as against the E2 protein of HCV, can prevent the binding of HCV to cells (28, 29). The potential importance of the HVR1 for HCV neutralization is also underscored by the analogy with the V3 loop of human immunodeficiency virus, which represents a principal neutralization domain and a major target of type-specific neutralizing antibodies (30).

To investigate whether the HVR1 of the E2 protein is a critical neutralization domain, *in vitro* neutralization of a pedigreed, *in vivo*-titrated HCV strain (H77) was attempted with a rabbit hyperimmune serum raised against a homologous synthetic HVR1 peptide. The residual infectivity was evaluated by inoculation of HCV-seronegative chimpanzees.

MATERIALS AND METHODS

▶Top
▶Abstract
▶Introduction

MATERIALS AND METHODS
RESULTS
DISCUSSION
References

Source of HCV. The virus stock of HCV used for all the inocula was derived from a plasmapheresis unit obtained during the early acute phase of posttransfusion non-A, non-B hepatitis (on July 12, 1977) from a patient (H) who underwent open heart surgery (31). This plasma, designated H77, contained $10^{6.5}$ 50% chimpanzee-infectious doses (CID₅₀) of HCV per ml, as shown by titration studies in chimpanzees (32) and was devoid of antibodies to HCV by all available tests. This viral stock has been used successfully to transmit non-A, non-B (NANB) hepatitis to chimpanzees in other studies (7, 14, 32).

Synthesis of the HVR1 Peptides and Generation of the Hyperimmune Sera. Two synthetic peptides (HVR1-A and HVR1-B; see Fig. 1) of 21 and 31 amino acids, respectively, corresponding to the sequence of the HVR1 of H77 were generated. The two sequences were obtained independently in our laboratory by direct sequencing, following PCR amplification of cDNA from the same sample (H77). One of the two sequences was previously reported (23). Peptides HVR1-A and HVR1-B were conjugated to tetanus antitoxin either by glutaraldehyde (HVR1-A) or by carbodiimide (HVR1-B) coupling. Hyperimmune sera were generated by three sequential intradermal multiple site injections in rabbits of the peptide conjugate (500 µg) in Freund's adjuvant according to a standard immunization protocol for rabbits (0, 1, and 6 months). The hyperimmune sera, designated LMF87 (anti-HVR1-A) and LMF92 (anti-HVR1-B), respectively, were tested in ELISA both against the homologous peptide (unconjugated) and against the recombinant E1/E2 complex from the H77 isolate expressed in vaccinia virus in BHK21 cells. The recombinant clone expressed in vaccinia had an HVR1 sequence identical to that of the HVR1-B peptide. As a control, the hyperimmune sera were tested against cell extracts of BHK21 infected with negative control recombinant vaccinia virus.

Source of Antibodies for Neutralization. As a potential source of neutralizing antibodies, we used the hyperimmune rabbit serum (LMF87, anti-HVR1) which was positive by ELISA against the homologous peptide and the recombinant E1/E2 protein complex, expressed in vaccinia systems. As negative controls, we used the preimmune rabbit serum that was negative by ELISA for all detectable antibodies to HCV, and plasma from a normal blood donor, negative for all antibodies to HCV (11), whose blood repeatedly failed to transmit hepatitis after transfusion (H.J.A., unpublished data). As a positive control, we used plasma obtained from patient H 2 years after primary infection, designated H79, which was previously shown to contain neutralizing antibodies against H77 (11). The H79 plasma was positive for antibodies to core, E1, E2, NS3, NS4, and NS5 of HCV (11).

In Vitro Neutralization Test. The neutralization test was performed as described (11). Each antiserum was diluted 1:5 in PBS (pH 7.4) and then heat-inactivated at 56°C for 30 min before use. One vial of a dilution (in fetal bovine serum) of the challenge virus containing 3200 CID₅₀ was further diluted 1:5 in ice-cold PBS (pH 7.4), and then one additional dilution was

made in cold PBS with 20% fetal bovine serum to yield samples containing 64 CID₅₀. The *in vitro* neutralization test was done by mixing the virus inoculum (64 CID₅₀ in 1 ml) with one of the inactivated antisera (1 ml). The virus/antiserum mixtures were incubated overnight at 4°C. Each mixture (2 ml) was then inoculated intravenously into one HCV-seronegative chimpanzee.

Chimpanzees. Five chimpanzees were included in this study. The animals were caged individually and maintained under conditions that met all relevant requirements for the use of primates in an approved facility. None of the chimpanzees included in this study had been previously exposed to HCV, and none of them had signs of active or past HCV infection, as measured by PCR and antibody testing. At the time of the study, all chimpanzees were negative for hepatitis B surface antigen and had normal hepatic enzyme levels. Weekly serum samples were monitored for alanine aminotransferase (ALT). Serum HCV RNA was determined in serial serum samples obtained at intervals of 1, 2, or 4 weeks, during an observation period of 24 weeks after the virus challenge. All serial samples were tested with a set of nested primers derived from the 5' noncoding region of the HCV genome (7). Serum HCV RNA from selected samples obtained from each chimpanzee 2 weeks after inoculation was amplified with a set of primers that span part of the E1 and E2 genes (7), including the HVR1, and the PCR products were sequenced both directly and after molecular cloning. Weekly serum samples were also tested for antibodies to HCV (anti-HCV).

Anti-HCV Testing. Antibodies against structural and nonstructural proteins of HCV (anti-HCV) were assayed in chimpanzee sera using a second generation ELISA according to the manufacturer's instructions (Ortho Diagnostics).

RNA Extraction and PCR. Total RNA extracted from 100 µl of serum or plasma using the guanidinium/phenol/chloroform method (33) was reverse-transcribed in a volume of 20 µl, and the resulting cDNA was amplified in a 100-µl reaction volume (33). PCR was performed using two sets of nested primers (7). The first, derived from the 5' noncoding region (7), was used to investigate the course of HCV viremia, and the second, derived from the E1 and E2 genes (7), including the HVR1, for the comparative sequence analysis. The sensitivity, specificity, and details of our nested PCR technique, have been reported (7, 33). To reduce the risk of contamination, all the proper precautions were taken (7, 33). In addition, for each test sample, a negative control was tested in parallel throughout the entire procedure, starting from RNA extraction.

Sequencing Analysis. PCR products amplified with the set of primers that span part of the E1 and E2 genes of the HCV genome, obtained from the H77 inoculum and from a selected sample from each chimpanzee, were purified by GeneClean (Bio 101). Double-stranded PCR fragments were directly sequenced by the dideoxynucleotide chain termination method with phage T7

DNA polymerase (Sequenase: United States Biochemical), as described (34). The amplified PCR products were also cloned into pGEM-T vector systems (Promega), and the molecular clones were sequenced using the Applied Biosystems model 373 automated DNA sequencer with a modified Sanger method. A total of 104 molecular clones from the H77 inoculum and 9 or 10 clones from each chimpanzee, on a sample obtained 2 weeks after inoculation, were sequenced.

RESULTS

▶Top
▶Abstract
▶Introduction
MATERIALS AND
METHODS
▶RESULTS
▶DISCUSSION
▶References

Generation of Rabbit Hyperimmune Sera Against the HVR1 and *in Vitro* Neutralization. We generated rabbit hyperimmune sera directed against two synthetic peptides corresponding to the HVR1 of HCV, strain H77, a pedigreed virus obtained during the early acute phase of post-transfusion NANB hepatitis from a patient (H) who underwent open heart surgery (31). Two separate aliquots of the H77 plasma were PCR-amplified with a set of primers spanning a portion of the E1 and E2 genes (7), including the HVR1 domain, and the DNA products were analyzed by direct sequencing (Fig. 1). Comparative analysis of the two predicted amino acid sequences of 191 residues showed only a single amino acid change (S → N at position 391), located within the HVR1 (Fig. 1). Based on these data, two synthetic peptides, representing the two sequences of the HVR1 of H77, were generated, and each of them was separately used to immunize two rabbits. One peptide (HVR1-A), bearing the S residue at position 391, was shorter (aa 390–410); the other (HVR1-B), bearing the N residue at position 391, was longer (aa 384–414). The hyperimmune sera, designated LMF87 (anti-HVR1-A) and LMF92 (anti-HVR1-B), respectively, were both reactive in an ELISA test against the homologous peptide (at a titer of 1:650,000), but only LMF87, directed against the shorter peptide (HVR1-A), recognized the recombinant E1/E2 protein complex derived from the H77 virus and expressed in a vaccinia system (at a titer of 1:70,000). Thus, the LMF87 anti-HVR1 serum was selected for *in vitro* neutralization experiments.

The chimpanzees and sera used in the experiments of HCV neutralization *in vitro* are indicated in Table 1. As negative controls, we used the respective preimmune rabbit serum and plasma from a normal blood donor, which were both negative for detectable antibodies to HCV. As a positive control, we used plasma obtained from patient H 2 years after primary infection, designated H79, which was previously shown to contain neutralizing antibodies against H77 (11). The protocol used for the neutralization test has been reported (11). The challenge stock was prepared from the standard H77 inoculum which contained $10^{6.5}$ CID₅₀ of HCV per milliliter, as determined by *in vivo* titration in chimpanzees (32). This inoculum had been used successfully for other challenge studies in chimpanzees (7, 11, 32). The *in vitro* neutralization test was performed by mixing the virus inoculum (64 CID₅₀ in 1 ml) with the relevant serum (1 ml), previously heat-inactivated at 56°C for 30 min. The virus/serum mixtures were incubated overnight at 4°C and then inoculated i.v.

into seronegative chimpanzees (Table 1). The dose of H77 virus used in this study (64 CID₅₀) had successfully infected five of five chimpanzees in a previous study (11).

Course of HCV Infection in Chimpanzees After Antibody-Mediated *in Vitro* Neutralization. After antibody-mediated *in vitro* neutralization, tests for residual infectivity were performed by intravenous inoculation of the serum/virus mixture into seronegative chimpanzees, the most sensitive model presently available to evaluate the infectivity of HCV (35). The two control animals (nos. 1480 and 1479) developed classical hepatitis C (Fig. 2A). Serum HCV RNA, as measured by PCR, was detected in the first bleeding, 1 week postinoculation, and remained persistently detectable throughout the observation period. Both animals seroconverted. In contrast, of the two animals whose inoculum contained the H77 virus mixed with the rabbit hyperimmune anti-HVR1 serum, one (no. 1484) did not show any virologic, biochemical or serologic evidence of HCV infection (Fig. 2B). Serum HCV RNA was never detected by PCR in any of the weekly samples tested throughout the observation period of 24 weeks; neither alterations in serum ALT levels nor antibody seroconversion occurred at any time after challenge. The second animal (no. 1486) developed acute hepatitis C, characterized by the appearance of HCV viremia within 1 week postinoculation and by elevation of serum ALT values and antibody seroconversion. The infection became chronic (Fig. 2B). Of the two chimpanzees whose inoculum contained the virus mixed with the H79 plasma, one (no. 1475) developed acute hepatitis, whereas the other (no. 1442), which was previously described (11), exhibited no signs of HCV infection or biochemical alterations (Fig. 2C). Thus, both the hyperimmune anti-HVR1 serum and the H79 plasma conferred protection from HCV infection in one of the two animals tested.

Sequence Analysis of the H77 Virus Used for Inoculation. To interpret the results of the neutralization experiments, we performed an extensive sequence analysis of the H77 virus that was used for inoculation. RNA from the H77 viral stock was extracted, reverse transcribed, and amplified with a set of primers that span a portion of the E1/E2 region, including the HVR1 (7). The PCR products, 573 nt long, were purified and analyzed by both direct sequencing and sequencing of molecular clones. From the H77 viral stock, a total of 104 molecular clones was analyzed. The predicted amino acid sequences of the HVR1 are shown in Fig. 3. At least 19 different viral strains were simultaneously present within the H77 virus stock, confirming that HCV circulates *in vivo* as a complex quasispecies. One variant was predominant, representing 70/104 clones (67%). The sequence of this variant was identical, except for a single amino acid change (S → N at position 391), to the synthetic peptide HVR1-A which had been used to generate the hyperimmune serum (LMF 87) selected for the *in vitro* neutralization studies, as well as to one of the two sequences obtained by direct sequencing (Fig. 1). Other strains were represented by only six, five, four, and two clones, respectively. At least 11 strains were represented by a single clone (Fig. 3).

Comparative Sequence Analysis of the Viral Quasispecies Present in the H77 Inoculum and the Viruses Recovered from the Infected Chimpanzees. We performed a comparative sequence analysis of the viral strains present in the H77 inoculum and the viruses recovered from the chimpanzees that developed HCV infection after challenge. From each chimpanzee, both direct sequencing and sequencing of 9 or 10 molecular clones were performed on a sample obtained 2 weeks after inoculation (Fig. 4). Remarkably, in the animal whose inoculum contained the virus mixed with the hyperimmune rabbit anti-HVR1 serum (no. 1486), neither the sequence of the 10 molecular clones nor the direct sequence was identical to the predominant clone against which the hyperimmune serum was directed. The viruses emerging from this animal were identical to two of the minor variants: 7 of the 10 clones corresponded to the second variant (6%) in the H77 quasispecies; the remaining 3 clones, as well as the directly determined sequence, corresponded to a variant represented by only 2% of the H77 quasispecies (Figs. 3 and 4). When compared with the sequence of the predominant strain of H77 virus used for challenge (Figs. 3 and 4), each of the two minor variants exhibited 4 amino acid changes over the 31 amino acids of the HVR1. In contrast, viruses identical to the predominant clone were consistently recovered from all the other chimpanzees, regardless of the serum used for neutralization. Altogether, these data indicate that in animal no. 1486 the rabbit hyperimmune anti-HVR1 serum was able to neutralize the predominant clone against which it had been raised, but was ineffective against some of the minor variants that emerged *in vivo*. Comparative sequence analysis was also performed in animal no. 1475, which developed acute hepatitis despite the presence in the inoculum of the H79 plasma, previously shown to contain neutralizing antibodies (11). The analysis demonstrated that the virus emerging *in vivo* was identical to the predominant clone (67% of the H77 viral quasispecies). Only a single amino acid change was detected in two of the nine clones. Similarly, the sequence obtained by direct sequencing corresponded to that of the predominant clone. Because this animal exhibited a biphasic pattern of serum ALT levels (Fig. 2C), raising the possibility that the second peak of hepatitis might be due to the emergence of a neutralization escape mutant, additional direct sequence analysis was performed over a period of 6 months after inoculation. Comparison of the sequences obtained 8, 12, 13, 18, and 25 weeks, respectively, postinoculation demonstrated 100% identity with the direct sequence obtained at week 2 postinoculation (Fig. 4). Remarkably, none of the minor variants was ever detected in this chimpanzee, which suggests that the *in vitro* neutralization was incomplete, and that HCV infection in this animal was initiated by a very limited number of viral particles of the predominant strain that were not effectively neutralized. These data support the hypothesis that the neutralizing immune response elicited by HCV in the host is weak, and further demonstrate the extreme sensitivity of the animal model for evaluating HCV infectivity (35).

►Top
►Abstract
►Introduction
MATERIALS AND
METHODS
►RESULTS
►DISCUSSION
►References

DISCUSSION

Our study provides evidence that the HVR1 of the E2 protein of HCV, the most variable region of the entire viral genome, is a critical neutralization domain. We showed that a hyperimmune rabbit serum raised against a synthetic peptide representing the HVR1 protected chimpanzees from homologous HCV infection, but not from the emergence of neutralization escape mutants that were already present in the complex viral quasispecies. These results indicate that the synthetic peptide had elicited neutralizing antibodies, but that such antibodies were type-specific and thus ineffective against some of the minor variants present in the inoculum. In fact, the rabbit anti-HVR1 hyperimmune serum was directed against the predominant clone present in the H77 plasma, which contained a mixed viral population (quasispecies) of at least 19 different variants. Thus, this study provides an *in vivo* model for the emergence of neutralization escape mutants, a strategy whereby HCV can evade the host's immune surveillance and establish persistent infection in >80% of infected individuals (4). Neutralization escape mutants emerged in only one of the two animals whose inoculum contained the virus mixed with the hyperimmune anti-HVR1 serum, whereas the other chimpanzee was completely protected. A possible explanation for this finding is the different infectivity titer of each of the 19 viral variants present in the H77 inoculum. In fact, the two variants recovered from this animal represented only 6% and 2%, respectively, of the viral population of the H77 used for inoculation. Thus, the viral inoculum of 64 CID₅₀ contained only ≈ 4 and 1 CID₅₀, respectively, of these variants. These represent borderline titers for *in vivo* infectivity, which would not be expected to infect 100% of the animals, based on Poisson distributions of the variant viruses.

The observation that a hyperimmune serum against the HVR1 protected chimpanzees from homologous HCV infection provides direct evidence that anti-HVR1 antibodies can, in the absence of other virus-specific immune responses, prevent HCV infection. The HCV-neutralizing activity mediated by anti-HVR1 antibodies may be the experimental correlate of an *in vivo* protective immune response. Protection against the homologous strain of HCV was demonstrated in chimpanzees vaccinated with the recombinant putative E1/E2 proteins of HCV (36). The finding that HVR1 is a neutralization domain of HCV constitutes an important step for understanding the immune response elicited by HCV in the host, as well as for devising effective preventive strategies for the control of HCV infection. However, the fact that a major target of the neutralizing antibodies is the HVR1, the most variable region of the HCV genome, raises a new set of problems that need to be addressed for the development of a broadly reactive vaccine against HCV. For a vaccine to be practical in humans, it should provide protection against the great variety of HCV isolates that infect the human population. The high degree of genetic heterogeneity of HCV (6), which is reflected in the complex quasispecies nature of this virus (37), indicates that it might be difficult to realize effective preventive strategies. Nevertheless, our report demonstrates

that it is indeed possible to elicit a protective humoral immune response against homologous HCV infection. However, because there is no obvious strategy to suppress the genetic variation of HCV, the finding that the HVR1 is a neutralization domain poses a major challenge that must be taken into account for any viable vaccination strategy for the control of HCV infection.

Footnotes

Abbreviations: HCV, hepatitis C virus; HVR1, hypervariable region 1; E1, envelope glycoprotein 1; E2, envelope glycoprotein 2; CID₅₀, 50% chimpanzee-infectious dose; NANB, non-A, non-B; ALT, alanine aminotransferase.

References

Top
Abstract
Introduction
MATERIALS AND
METHODS
RESULTS
DISCUSSION
References

1. IARC Working Group, World Health Organization: Hepatitis C Virus. (1994). *IARC Monogr.* 59, 165-221
2. Kiyosawa, K., Tanaka, E., Sodeyama, T., & Furuta, S. (1994). *Intervirolgy* 37, 101-107 [PubMed]
3. Bellentani, S., Tiribelli, C., Saccoccio, G., Sodde, M., Fratti, N., De Martin, C., Cristianini, G., & The Dyonyos Study Group. (1994). *Hepatology* 20, 1442-1449 [PubMed]
4. Alter, H. J. & Seeff, L. B. Zuckerman, A. Z. & Thomas, H. C., eds. (1994) in *Viral Hepatitis: Scientific Basis and Clinical Management* (Churchill Livingstone, Edinburgh)
5. Nishioka, K., Watanabe, J., Furuta, S., Tanaka, E., Iino, S., Suzuki, H., Tsuji, T., Yano, M., Kuo, G., Choo, Q.-L., Houghton, M., & Oda, T. (1991). *Cancer (Philadelphia)* 67, 429-433
6. Bukh, J., Miller, R. H., & Purcell, R. H. (1995). *Semin. Liver Dis.* 15, 41-63 [PubMed]
7. Farci, P., Alter, H. J., Govindarajan, S., Wong, D. C., Engle, R., Lesniewski, R. R., Mushahwar, I. K., Desai, S. M., Miller, R. H., Ogata, N., & Purcell, R. H. (1992). *Science* 258, 135-140 [PubMed]
8. Lai, M. E., Mazzoleni, A. P., Argioli, F., De Virgilis, S., Balestrieri, A., Purcell, R. H., & Farci, P. (1994). *Lancet* 343, 388-390 [PubMed]
9. Kao, J. K., Chen, P. J., Lai, M. Y., & Chen, D. S. (1992). *Gastroenterology* 105, 583-587

10. Okamoto, H., Mishiro, S., Tokita, H., Tsuda, F., Miyarawa, Y., & Mayumi, M. (1994). *Hepatology* **20**, 1131–1136 [[PubMed](#)]
11. Farci, P., Alter, H. J., Wong, D. C., Miller, R. H., Govindarajan, S., Engle, R., Shapiro, M., & Purcell, R. H. (1994). *Proc. Natl. Acad. Sci. USA* **91**, 7792–7796 [[PubMed](#)] [[Full text in PMC](#)]
12. Shimizu, Y. K., Hijikata, M., Iwamoto, A., Alter, H. J., Purcell, R. H., & Yoshikura, H. (1994). *J. Virol.* **68**, 1494–1500 [[PubMed](#)]
13. Choo, Q.-L., Richman, K. H., Han, J. H., Berger, K., Lee, C., Dong, C., Gallegos, C., Coit, D., Medina-Selby, A., Barr, P. J., Weiner, A. J., Bradley, D. W., Kuo, G., & Houghton, M. (1991). *Proc. Natl. Acad. Sci. USA* **88**, 2451–2455 [[PubMed](#)] [[Full text in PMC](#)]
14. Weiner, A. J., Brauer, M. J., Roseblatt, J., Richman, K. H., Tung, J., Crawford, K., Bonino, F., Saracco, G., Choo, Q.-L., & Houghton, M. (1991). *Virology* **180**, 842–848 [[PubMed](#)]
15. Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M., Ohkoshi, S., & Shimotohno, K. (1991). *Biochem. Biophys. Res. Commun.* **175**, 220–228 [[PubMed](#)]
16. Weiner, A. J., Geysen, H. M., Christopherson, C., Hall, J. E., Mason, T. J., Saracco, G., Bonino, F., Crawford, K., Marion, C. D., Crawford, K. A., Brunetto, M., Barr, P. J., Miyamura, T., McHutchinson, J., & Houghton, M. (1992). *Proc. Natl. Acad. Sci. USA* **89**, 3468–3472 [[PubMed](#)] [[Full text in PMC](#)]
17. Taniguchi, S., Okamoto, H., Sakamoto, M., Kojima, M., Tsuda, F., Tanaka, T., Munekata, E., Muchmore, E. E., Peterson, D. A., & Mishiro, S. (1993). *Virology* **195**, 297–301 [[PubMed](#)]
18. Kato, N., Sekiya, H., Ootsuyama, Y., Nakazawa, T., Hijikata, M., Ohkoshi, S., & Shimotohno, K. (1993). *J. Virol.* **67**, 3923–3930 [[PubMed](#)]
19. Kato, N., Ootsuyama, Y., Sekiya, H., Ohkoshi, S., Nakazawa, T., Hijikata, M., & Shimotohno, K. (1994). *J. Virol.* **68**, 4776–4784 [[PubMed](#)]
20. Sekiya, H., Kato, N., Ootsuyama, Y., Nakazawa, T., Yamauchi, K., & Shimotohno, K. (1994). *Int. J. Cancer* **57**, 664–670 [[PubMed](#)]
21. Lesniewski, R. R., Boardway, K. M., Casey, J. M., Desai, S. M., Devare, S. G., Leung, T. K., & Mushahwar, I. K. (1993). *J. Med. Virol.* **40**, 150–156 [[PubMed](#)]

22. Scarselli, E., Cerino, A., Esposito, G., Silini, E., Mondelli, M. U., & Traboni, C. (1995). *J. Virol.* **69**, 4407–4412 [[PubMed](#)]
23. Ogata, N., Alter, H. J., Miller, R. H., & Purcell, R. H. (1991). *Proc. Natl. Acad. Sci. USA* **88**, 3392–3396 [[PubMed](#)] [[Full text in PMC](#)]
24. Okamoto, H., Kojima, M., Okada, S.-I., Yoshizawa, H., Iizuka, H., Tanaka, T., Muchmore, E. E., Peterson, D. A., Ito, Y., & Mishiro, S. (1992). *Virology* **190**, 894–899 [[PubMed](#)]
25. Higashi, Y., Kakumu, S., Yoshioka, K., Wakita, T., Mizokami, M., Ohba, K., Ito, T., Ishikawa, T., Takayanagi, M., & Nagai, Y. (1993). *Virology* **197**, 659–668 [[PubMed](#)]
26. Kumar, U., Brown, J., Monjardino, J., & Thomas, H. C. (1993). *J. Infect. Dis.* **167**, 726–730 [[PubMed](#)]
27. Kumar, U., Monjardino, J., & Thomas, H. C. (1994). *Gastroenterology* **106**, 1072–1075
28. Zibert, A., Schreier, E., & Roggendorf, M. (1995). *Virology* **208**, 663–661
29. Rosa, D., Campagnoli, S., Moretto, C., Guenzi, E., Cousens, L., Chin, M., Dong, C., Weiner, A. J., Lau, J. Y. N., Choo, Q.-L., Chien, D., Pileri, P., Houghton, M., & Abrignani, S. (1996). *Proc. Natl. Acad. Sci. USA* **93**, 1759–1763 [[PubMed](#)] [[Full text in PMC](#)]
30. Letvin, N. L. (1993). *N. Engl. J. Med.* **329**, 1400–1405 [[PubMed](#)]
31. Koziol, D. E., Holland, P. V., Alling, D. W., Melpolder, J. C., Solomon, R. E., Purcell, R. H., Hudson, L. M., Shoup, F. J., Krakauer, H., & Alter, H. J. (1986). *Ann. Intern. Med.* **104**, 488–495 [[PubMed](#)]
32. Feinstone, S. M., Alter, H. J., Dienes, H., Shimizu, Y. K., Popper, H., Blackmore, D., Sly, D., London, W. T., & Purcell, R. H. (1981). *J. Infect. Dis.* **144**, 588–598 [[PubMed](#)]
33. Farci, P., Alter, H. J., Wong, D., Miller, R. H., Shih, J. W., Jett, B., & Purcell, R. H. (1991). *N. Engl. J. Med.* **325**, 98–104 [[PubMed](#)]
34. Bachman, B., Luke, W., & Hunsmann, G. (1990). *Nucleic Acids Res.* **18**, 1309 [[PubMed](#)]
35. Farci, P. & Purcell, R. H. Zuckerman, A. & Thomas, H. C., eds. (1993) in *Viral Hepatitis: Scientific Basis and Clinical Management* (Churchill

Livingstone, Edinburgh)

36. Choo, Q.-L., Kuo, G., Ralston, R., Weiner, A. J., Chien, D., Van Nest, G., Han, J., Berger, K., Thudium, K., Kuo, C., Kansopon, J., McFarland, J., Tabrizi, A., Ching, K., Moss, B., Cummins, L. B., Houghton, M., & Muchmore, E. (1994). *Proc. Natl. Acad. Sci. USA* **91**, 1294–1298 [PubMed] [Full text in PMC]
37. Martell, M., Esteban, J. I., Quer, J., Genesca, J., Weiner, A., Esteban, R., Guardia, J., & Gomez, J. (1992). *J. Virol.* **66**, 3225–3229 [PubMed]

Figures and Tables




Figure 1. Alignment of the amino acid sequences (in single-letter code) predicted from a portion of the E1 and E2 genes of HCV, strain H77, spanning map positions 317–508 (13).




Figure 2. Course of HCV infection in chimpanzees after antibody-mediated *in vitro* neutralization.




Figure 3. Predicted amino acid sequence alignment of 31 amino acids (in single-letter code) representing HVR1 of the E2 gene, spanning map position 384–414, of 104 molecular clones obtained from HCV, strain H77, which was used for inoculation.




Figure 4. Comparative sequence analysis of the sequence of the H77 virus used for inoculation and the viruses recovered from the chimpanzees 2 weeks after inoculation.

Table 1. *In vitro* neutralization of HCV, as measured in chimpanzees: animals and antisera used

Copyright © 1996, The National Academy of Sciences of the USA

[Write to PMC](#) [Privacy Policy](#) [Disclaimer](#)

[PMC Home](#) [PubMed](#) [NCBI](#) [NLM](#) [NIH](#)